NRX Pharmaceuticals, Inc.

NRXP

Financials

10-QQ2 ended 06/30/2608/14/26 10-QQ1 ended 03/31/2605/15/26 10-KFY 202503/23/26 10-QQ3 ended 09/30/2511/14/25 10-QQ2 ended 06/30/2508/18/25

Disclosures

8-KCurrent report10/16/26 8-KCurrent report10/05/26 8-KCurrent report09/16/26 8-KCurrent report09/14/26 8-KCurrent report08/17/26

Prospectuses and Registrations

424B5Prospectus supplement06/03/26 424B5Prospectus supplement06/02/26 424B5Prospectus supplement02/17/26 424B3Prospectus12/22/25 S-3/AShelf registration (amended)12/12/25

Proxies

DEFA14AAdditional proxy materials02/24/26 DEF 14ADefinitive proxy02/23/26 PRE 14APreliminary proxy02/13/26 DEF 14ADefinitive proxy09/05/24 PRE 14APreliminary proxy08/27/24

Ownership

SC 13G/ABeneficial ownership (amended)05/15/26 Form 3Initial insider ownership02/17/26 Form 4Insider transaction02/17/26 Form 4Insider transaction09/10/25 Form 4Insider transaction09/10/25

Other

25-NSERemoval from listing05/22/26 ARSAnnual report to shareholders02/23/26 EFFECTRequest for effectiveness12/22/25 CORRESPCorrespondence with the SEC12/18/25 NT 10-QLate filing notification (10-Q)08/14/25